December 30, 2020

Odan Laboratories Ltd., a fast growing Canadian pharmaceutical company, is proud to announce that it has
acquired Ilkos Therapeutic Inc. (“Ilkos”), a Montreal based clinical stage Biopharmaceutical company, for the
development and commercialization of its lead compound S42909 to be used for the treatment of Venous
Leg Ulcers.
Ilkos obtained a worldwide and exclusive licence from Servier for its novel compound, S42909, indicated for
the oral treatment of venous lower limb ulcers.
The vision of Ilkos is to make a difference in the lives of patients suffering from venous lower limb ulcers, a
disease that affects 1% to 1.5% of the population, mainly older people, by offering them the first disease-
modifying oral treatment. This represents a potential clinical breakthrough.
The mission of lkos is to demonstrate the efficacy and safety of compound S42909.
“With the acquisition of Ilkos, Odan once again continues to expand and diversify its R&D activities,”
expressed Howard Kaminsky, President of Odan. “We are confident in the potential of Ilkos’s S42909
compound to be profitable in the future to Odan.”